Department of Stem Cells & Regenerative Medicine, D Y Patil Education Society (Deemed University), E 869 D. Y. Patil Vidyanagar, KasbaBawda, Kolhapur, 416006, MS, India.
Department of Stem Cells & Regenerative Medicine, D Y Patil Education Society (Deemed University), E 869 D. Y. Patil Vidyanagar, KasbaBawda, Kolhapur, 416006, MS, India.
Placenta. 2020 Sep 15;99:117-130. doi: 10.1016/j.placenta.2020.07.033. Epub 2020 Aug 6.
The current challenge of the COVID-19 pandemic is complicated by the limited therapeutic options against the virus, with many being anecdotal or still undergoing confirmatory trials, underlining the urgent need for novel strategies targeting the virus. The pulmotropic virus causes loss of oxygenation in severe cases with acute respiratory distress syndrome (ARDS) and need for mechanical ventilation. This work seeks to introduce placental extract-derived biologically active components as a therapeutic option and highlights their mechanism of action relevant to COVID-19 virus. Human placenta has been used in clinical practice for over a century and there is substantial experience in clinical applications of placental extract for different indications. Aqueous extract of human placentacontains growth factors, cytokines/chemokines, natural metabolic and other compounds, anti-oxidants, amino acids, vitamins, trace elements and biomolecules, which individually or in combination show accelerated cellular metabolism, immunomodulatory and anti-inflammatory effects, cellular proliferation and stimulation of tissue regeneration processes. Placental extract treatment is proposed as a suitable therapeutic approach consideringthe above properties which could protect against initial viral entry and acute inflammation of alveolar epithelial cells, reconstitute pulmonary microenvironment and regenerate the lung. We reviewed useful therapeutic information of placental biomolecules in relation to COVID-19 treatment. We propose the new approach of using placental growth factors, chemokines and cytokine which will execute antiviral activity in coordination with innate and humoral immunity and improve patient's immunological responses to COVID-19. Executing a clinical trial using placental extract as preventive, protective and/or therapeutic approach for COVID-19treatment could advance the development of a most promising therapeutic candidate that can join the armamentaria against the COVID-19 virus.
当前 COVID-19 大流行的挑战因针对该病毒的治疗选择有限而变得复杂，其中许多选择都是轶事证据，或者仍在进行确证性试验，这突出表明迫切需要针对该病毒的新策略。这种肺病毒在伴有急性呼吸窘迫综合征（ARDS）和需要机械通气的严重病例中导致氧合丧失。这项工作旨在介绍胎盘提取物衍生的生物活性成分作为一种治疗选择，并强调其与 COVID-19 病毒相关的作用机制。人类胎盘在临床实践中已使用了一个多世纪，并且在针对不同适应症的胎盘提取物的临床应用方面具有丰富的经验。人胎盘的水提取物含有生长因子、细胞因子/趋化因子、天然代谢物和其他化合物、抗氧化剂、氨基酸、维生素、微量元素和生物分子，它们单独或组合使用可加速细胞代谢、免疫调节和抗炎作用、细胞增殖和刺激组织再生过程。鉴于上述特性，胎盘提取物治疗被提议作为一种合适的治疗方法，可防止初始病毒进入和肺泡上皮细胞的急性炎症，重建肺微环境并再生肺。我们回顾了与 COVID-19 治疗相关的胎盘生物分子的有用治疗信息。我们提出了使用胎盘生长因子、趋化因子和细胞因子的新方法，这些方法将与先天和体液免疫协调执行抗病毒活性，并改善患者对 COVID-19 的免疫反应。使用胎盘提取物作为 COVID-19 治疗的预防、保护和/或治疗方法进行临床试验，可能会推进最有前途的治疗候选药物的开发，使其成为对抗 COVID-19 病毒的武器库的一部分。
